1
|
Fouda A, Negi S, Zaremba O, Gaidar RS, Moroz YS, Rusanov E, Paraskevas S, Tchervenkov J. Discovery, Synthesis, and In Vitro Characterization of 2,3 Derivatives of 4,5,6,7-Tetrahydro-Benzothiophene as Potent Modulators of Retinoic Acid Receptor-Related Orphan Receptor γt. J Med Chem 2023; 66:7355-7373. [PMID: 37172324 PMCID: PMC10259452 DOI: 10.1021/acs.jmedchem.3c00021] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Indexed: 05/14/2023]
Abstract
Retinoic acid receptor-related orphan receptor γt (RORγt) is a nuclear receptor that is expressed in a variety of tissues and is a potential drug target for the treatment of inflammatory and auto-immune diseases, metabolic diseases, and resistant cancer types. We herein report the discovery of 2,3 derivatives of 4,5,6,7-tetrahydro-benzothiophene modulators of RORγt. We also report the solubility in acidic/neutral pH, mouse/human/dog/rat microsomal stability, Caco-2, and MDR1-MDCKII permeabilities of a set of these derivatives. For this group of modulators, inverse agonism by steric clashes and push-pull mechanisms induce greater instability to protein conformation compared to agonist lock hydration. Independent of the two mechanisms, we observed a basal modulatory activity of the tested 2,3 derivatives of 4,5,6,7-tetrahydro-benzothiophene toward RORγt due to the interactions with the Cys320-Glu326 and Arg364-Phe377 hydrophilic regions. The drug discovery approach reported in the current study can be employed to discover modulators of nuclear receptors and other globular protein targets.
Collapse
Affiliation(s)
- Ahmed Fouda
- Department
of Experimental Surgery, McGill University, Montréal, Québec H3G 1A4, Canada
- Research
Institute of the McGill University Health Centre, Montréal, Québec H3H 2R9, Canada
| | - Sarita Negi
- Research
Institute of the McGill University Health Centre, Montréal, Québec H3H 2R9, Canada
| | | | | | - Yurii S. Moroz
- Chemspace
LLC, Kyïv 02094, Ukraine
- Taras
Shevchenko National University of Kyïv, Kyïv 01601, Ukraine
| | - Eduard Rusanov
- Institute
of Organic Chemistry, National Academy of
Sciences of Ukraine, Kyïv 02094, Ukraine
- Department
of Chemistry and Applied Biosciences, ETH
Zürich, Zürich CH-8093, Switzerland
| | - Steven Paraskevas
- Department
of Experimental Surgery, McGill University, Montréal, Québec H3G 1A4, Canada
- Research
Institute of the McGill University Health Centre, Montréal, Québec H3H 2R9, Canada
- Department
of Surgery, McGill University, Montréal, Québec H3G 1A4, Canada
- McGill
University Health Centre, Montréal, Québec H4A 3J1, Canada
| | - Jean Tchervenkov
- Department
of Experimental Surgery, McGill University, Montréal, Québec H3G 1A4, Canada
- Research
Institute of the McGill University Health Centre, Montréal, Québec H3H 2R9, Canada
- Department
of Surgery, McGill University, Montréal, Québec H3G 1A4, Canada
- McGill
University Health Centre, Montréal, Québec H4A 3J1, Canada
| |
Collapse
|
2
|
Zhang J, Chen B, Zhang C, Sun N, Huang X, Wang W, Fu W. Modes of action insights from the crystallographic structures of retinoic acid receptor-related orphan receptor-γt (RORγt). Eur J Med Chem 2023; 247:115039. [PMID: 36566711 DOI: 10.1016/j.ejmech.2022.115039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Revised: 11/29/2022] [Accepted: 12/19/2022] [Indexed: 12/24/2022]
Abstract
RORγt plays an important role in mediating IL-17 production and some tumor cells. It has four functional domains, of which the ligand-binding domain (LBD) is responsible for binding agonists to recruit co-activators or inverse agonists to prevent co-activator recruiting the agonists. Thus, potent ligands targeting the LBD of this protein could provide novel treatments for cancer and autoimmune diseases. In this perspective, we summarized and discussed various modes of action (MOA) of RORγt-ligand binding structures. The ligands can bind with RORγt at either orthosteric site or the allosteric site, and the binding modes at these two sites are different for agonists and inverse agonist. At the orthosteric site, the binding of agonist is to stabilize the H479-Y502-F506 triplet interaction network of RORγt. The binding of inverse agonist features as these four apparent ways: (1) blocking the entrance of the agonist pocket in RORγt; (2) directly breaking the H479-Y502 pair interactions; (3) destabilizing the triplet H479-Y502-F506 interaction network through perturbing the conformation of the side chain in M358 at the bottom of the binding pocket; (4) and destabilizing the triplet H479-Y502-F506 through changing the conformation of the side chain of residue W317 side chain. At the allosteric site of RORγt, the binding of inverse agonist was found recently to inhibit the activation of protein by interacting directly with H12, which results in unfolding of helix 11' and orientation of H12 to directly block cofactor peptide binding. This overview of recent advances in the RORγt structures is expected to provide a guidance of designing more potent drugs to treat RORγt-related diseases.
Collapse
Affiliation(s)
- Junjie Zhang
- School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China
| | - Baiyu Chen
- School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China
| | - Chao Zhang
- School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China
| | - Nannan Sun
- School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China
| | - Xiaoqin Huang
- Center for Research Computing, Office of Information Technology, Center for Theoretical Biological Physics, Rice University, Houston, TX, 77030, USA
| | - Wuqing Wang
- School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China
| | - Wei Fu
- School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China.
| |
Collapse
|
3
|
Pham B, Cheng Z, Lopez D, Lindsay RJ, Foutch D, Majors RT, Shen T. Statistical Analysis of Protein-Ligand Interaction Patterns in Nuclear Receptor RORγ. Front Mol Biosci 2022; 9:904445. [PMID: 35782874 PMCID: PMC9240913 DOI: 10.3389/fmolb.2022.904445] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Accepted: 05/16/2022] [Indexed: 11/21/2022] Open
Abstract
The receptor RORγ belongs to the nuclear receptor superfamily that senses small signaling molecules and regulates at the gene transcription level. Since RORγ has a high basal activity and plays an important role in immune responses, inhibitors targeting this receptor have been a focus for many studies. The receptor-ligand interaction is complex, and often subtle differences in ligand structure can determine its role as an inverse agonist or an agonist. We examined more than 130 existing RORγ crystal structures that have the same receptor complexed with different ligands. We reported the features of receptor-ligand interaction patterns and the differences between agonist and inverse agonist binding. Specific changes in the contact interaction map are identified to distinguish active and inactive conformations. Further statistical analysis of the contact interaction patterns using principal component analysis reveals a dominant mode which separates allosteric binding vs. canonical binding and a second mode which may indicate active vs. inactive structures. We also studied the nature of constitutive activity by performing a 100-ns computer simulation of apo RORγ. Using constitutively active nuclear receptor CAR as a comparison, we identified a group of conserved contacts that have similar contact strength between the two receptors. These conserved contact interactions, especially a couple key contacts in H11–H12 interaction, can be considered essential to the constitutive activity of RORγ. These protein-ligand and internal protein contact interactions can be useful in the development of new drugs that direct receptor activity.
Collapse
Affiliation(s)
- Bill Pham
- Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, United States
| | - Ziju Cheng
- Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, United States
| | - Daniel Lopez
- Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, United States
| | - Richard J. Lindsay
- UT-ORNL Graduate School of Genome Science and Technology, Knoxville, TN, United States
| | - David Foutch
- UT-ORNL Graduate School of Genome Science and Technology, Knoxville, TN, United States
| | - Rily T. Majors
- Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, United States
| | - Tongye Shen
- Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, United States
- *Correspondence: Tongye Shen,
| |
Collapse
|
4
|
Suri C, Awasthi A, Asthana S. Crystallographic landscape provides molecular insights into the modes of action of diverse ROR-γt modulators. Drug Discov Today 2021; 27:652-663. [PMID: 34838728 DOI: 10.1016/j.drudis.2021.11.022] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Revised: 08/13/2021] [Accepted: 11/19/2021] [Indexed: 12/24/2022]
Abstract
ROR-γt, the master regulator of Th-17 cells, is activated by the binding of small molecules at its orthosteric site, followed by the recruitment of co-activators or co-repressors in the ligand binding domain (LBD). Th-17 cells provide immune-dependent protection against cancers and pathogens. Their dysregulation causes inflammation and is therefore implicated in various autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and psoriasis. Consequently, there is enormous interest in the development of ROR-γt modulators, both agonist and inverse-agonists. Here, we review advances in the development of ROR-γt modulators that have been made over the past decade, focusing on the rich crystallography landscape for ROR-γt co-crystals that has delineated the relationship between the binding patterns of modulators and the resulting biological activities.
Collapse
Affiliation(s)
- Charu Suri
- Translational Health Science and Technology Institute (THSTI), Haryana 121001, India.
| | - Amit Awasthi
- Translational Health Science and Technology Institute (THSTI), Haryana 121001, India.
| | - Shailendra Asthana
- Translational Health Science and Technology Institute (THSTI), Haryana 121001, India.
| |
Collapse
|
5
|
Li Z, Liu T, He X, Bai C. The evolution paths of some reprehensive scaffolds of RORγt modulators, a perspective from medicinal chemistry. Eur J Med Chem 2021; 228:113962. [PMID: 34776280 DOI: 10.1016/j.ejmech.2021.113962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Revised: 10/19/2021] [Accepted: 10/27/2021] [Indexed: 11/29/2022]
Abstract
The ligand binding domain (LBD) of retinoid-related orphan nuclear receptor γt (RORγt) has been exploited as a promising target for the new small molecule therapeutics to cure autoimmune diseases via modulating the IL-17 and IL-22 production by Th17 cells. Diverse chemical scaffolds of these small molecules have been discovered by multiple groups with methods such as high throughput screening (HTS) and virtual screening. These different scaffolds are further developed by medicinal chemists to afford lead compounds the best of which enter clinical trials. In this review, we summarize these chemical scaffolds and their evolution paths according to the groups in which they have been discovered or studied. We combine the data of the chemistry, biological assays and structural biology of each chemical scaffold, in order to afford insight to develop new RORγt modulators with higher potency, less toxicity and elucidated working mechanism.
Collapse
Affiliation(s)
- Zhuohao Li
- Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China; Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China
| | - Tao Liu
- Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China; Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China
| | - Xixin He
- School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Chuan Bai
- Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China; Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China.
| |
Collapse
|
6
|
Aicher TD, Van Huis CA, Hurd AR, Skalitzky DJ, Taylor CB, Beleh OM, Glick G, Toogood PL, Yang B, Zheng T, Huo C, Gao J, Qiao C, Tian X, Zhang J, Demock K, Hao LY, Lesch CA, Morgan RW, Moisan J, Wang Y, Scatina J, Paulos CM, Zou W, Carter LL, Hu X. Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer. J Med Chem 2021; 64:13410-13428. [PMID: 34499493 DOI: 10.1021/acs.jmedchem.1c00731] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Retinoic acid receptor-related orphan receptor γ (RORc, RORγ, or NR1F3) is the nuclear receptor master transcription factor that drives the function and development of IL-17-producing T helper cells (Th17), cytotoxic T cells (Tc17), and subsets of innate lymphoid cells. Activation of RORγ+ T cells in the tumor microenvironment is hypothesized to render immune infiltrates more effective at countering tumor growth. To test this hypothesis, a family of benzoxazines was optimized to provide LYC-55716 (37c), a potent, selective, and orally bioavailable small-molecule RORγ agonist. LYC-55716 decreases tumor growth and enhances survival in preclinical tumor models and was nominated as a clinical development candidate for evaluation in patients with solid tumors.
Collapse
Affiliation(s)
- Thomas D Aicher
- Department of Chemistry, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States
| | - Chad A Van Huis
- Department of Chemistry, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States
| | - Alexander R Hurd
- Department of Chemistry, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States
| | - Donald J Skalitzky
- Department of Chemistry, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States
| | - Clarke B Taylor
- Department of Chemistry, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States
| | - Omar M Beleh
- Department of Chemistry, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States
| | - Gary Glick
- Chief Scientific Officer, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States
| | - Peter L Toogood
- Department of Chemistry, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States
| | - Bing Yang
- Department of Chemistry, Pharmaron Beijing, Co. Ltd., Beijing 100176, P. R. China
| | - Tao Zheng
- Department of Chemistry, Pharmaron Beijing, Co. Ltd., Beijing 100176, P. R. China
| | - Changxin Huo
- Department of Chemistry, Pharmaron Beijing, Co. Ltd., Beijing 100176, P. R. China
| | - Jie Gao
- Department of Chemistry, Pharmaron Beijing, Co. Ltd., Beijing 100176, P. R. China
| | - Chenxi Qiao
- Department of Chemistry, Pharmaron Beijing, Co. Ltd., Beijing 100176, P. R. China
| | - Xiaolong Tian
- Department of Chemistry, Pharmaron Beijing, Co. Ltd., Beijing 100176, P. R. China
| | - Junping Zhang
- Department of Chemistry, Pharmaron Beijing, Co. Ltd., Beijing 100176, P. R. China
| | - Kellie Demock
- Department of Biology, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States
| | - Ling-Yang Hao
- Department of Biology, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States
| | - Charles A Lesch
- Department of Biology, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States
| | - Rodney W Morgan
- Department of Biology, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States
| | - Jacques Moisan
- Department of Biology, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States
| | - Yahong Wang
- Department of Biology, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States
| | - JoAnn Scatina
- Department of Preclinical Development, Lycera Corp., 620 Germantown Pike, Plymouth Meeting, Pennsylvania 19462, United States
| | - Chrystal M Paulos
- Hollings Cancer Center, Medical University of South Carolina, 173 Ashley Avenue, MSC 509, Room 203, Charleston, South Carolina 29425, United States
| | - Weiping Zou
- School of Medicine, Department of Surgery, University of Michigan, 2101 Taubman Center, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, United States
| | - Laura L Carter
- Department of Biology, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States
| | - Xiao Hu
- Department of Biology, Lycera Corp., 1350 Highland Drive, Suite A, Ann Arbor, Michigan 48108, United States
| |
Collapse
|
7
|
Zou H, Yang N, Zhang X, Chen HW. RORγ is a context-specific master regulator of cholesterol biosynthesis and an emerging therapeutic target in cancer and autoimmune diseases. Biochem Pharmacol 2021; 196:114725. [PMID: 34384758 DOI: 10.1016/j.bcp.2021.114725] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 08/04/2021] [Accepted: 08/05/2021] [Indexed: 01/04/2023]
Abstract
Aberrant cholesterol metabolism and homeostasis in the form of elevated cholesterol biosynthesis and dysregulated efflux and metabolism is well recognized as a major feature of metabolic reprogramming in solid tumors. Recent studies have emphasized on major drivers and regulators such as Myc, mutant p53, SREBP2, LXRs and oncogenic signaling pathways that play crucial roles in tumor cholesterol metabolic reprogramming. Therapeutics such as statins targeting the mevalonate pathway were tried at the clinic without showing consistent benefits to cancer patients. Nuclear receptors are prominent regulators of mammalian metabolism. Their de-regulation often drives tumorigenesis. RORγ and its immune cell-specific isoform RORγt play important functions in control of mammalian metabolism, circadian rhythm and immune responses. Although RORγ, together with its closely related members RORα and RORβ were identified initially as orphan receptors, recent studies strongly support the conclusion that specific intermediates and metabolites of cholesterol pathways serve as endogenous ligands of RORγ. More recent studies also reveal a critical role of RORγ in tumorigenesis through major oncogenic pathways including acting a new master-like regulator of tumor cholesterol biosynthesis program. Importantly, an increasing number of RORγ orthosteric and allosteric ligands are being identified that display potent activities in blocking tumor growth and autoimmune disorders in preclinical models. This review summarizes the recent preclinical and clinical progress on RORγ with emphasis on its role in reprogramming tumor cholesterol metabolism and its regulation. It will also discuss RORγ functional mechanisms, context-specificity and its value as a therapeutic target for effective cancer treatment.
Collapse
Affiliation(s)
- Hongye Zou
- Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, California, USA
| | - Nianxin Yang
- Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, California, USA
| | - Xiong Zhang
- Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, California, USA
| | - Hong-Wu Chen
- Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, California, USA; UC Davis Comprehensive Cancer Center, University of California, Davis, Sacramento, California, USA; VA Northern California Health Care System, Mather, California, USA.
| |
Collapse
|
8
|
Sun N, Xie Q, Dang Y, Wang Y. Agonist Lock Touched and Untouched Retinoic Acid Receptor-Related Orphan Receptor-γt (RORγt) Inverse Agonists: Classification Based on the Molecular Mechanisms of Action. J Med Chem 2021; 64:10519-10536. [PMID: 34264059 DOI: 10.1021/acs.jmedchem.0c02178] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a potential drug target for autoimmune diseases with a clear biological mechanism in the Th17/IL-17 pathway. The "agonist lock", which is formed by residues His479-Tyr502-Phe506 in RORγt, makes H12 tightly contact H11 in a suitable conformation for coactivator binding and, thus, is related to RORγt transcriptional activation. The inverse agonism of RORγt is complex because not all RORγt inverse agonists directly break the agonist lock to interfere with coactivator recruitment and the transcription of RORγt. Here, we analyze the complex structures, binding modes, and biological activities of various RORγt inverse agonists and classify them as "agonist lock touched" and "agonist lock untouched" RORγt inverse agonists according to whether they infringe on the agonist lock directly or not. We aim at providing a comprehensive review and insights into drug discovery of RORγt inverse agonists.
Collapse
Affiliation(s)
- Nannan Sun
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China.,Key Laboratory of Metabolism and Molecular Medicine, the Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.,Fudan Zhangjiang Institute, Shanghai 201203, China.,Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China
| | - Qiong Xie
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China.,Fudan Zhangjiang Institute, Shanghai 201203, China
| | - Yongjun Dang
- Key Laboratory of Metabolism and Molecular Medicine, the Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.,Centre for Novel Target and Therapeutic Intervention, Chongqing Medical University, No. 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China
| | - Yonghui Wang
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China
| |
Collapse
|
9
|
Gege C. Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases - where are we presently? Expert Opin Drug Discov 2021; 16:1517-1535. [PMID: 34192992 DOI: 10.1080/17460441.2021.1948833] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Introduction: The transcription factor retinoic acid-related orphan receptor gamma t (RORγt) has been identified as the master regulator of TH17 cell differentiation and IL-17/22 production and is therefore an attractive target for the treatment of inflammatory diseases. Several orally or topically administered small molecule RORγt inverse agonists (RIAs) have progressed up to the end of clinical Phase 2.Areas covered: Based on publications and patent evaluations this review summarizes the evolution of the chemical matter for all 16 pharmaceutical companies, who develop(ed) a clinical-stage RIAs (until March 2021). Structure proposals for some clinical stage RIAs are presented and the outcome of the clinical trials is discussed.Expert opinion: So far, the clinical trials have been plagued with a high attrition rate. Main reasons were lack of efficacy (topical) or safety signals (oral) as well as, amongst other things, thymic lymphomas as seen with BMS-986251 in a preclinical study and liver enzyme elevations in humans with VTP-43742. Possibilities to mitigate these risks could be the use of RIAs with different chemical structures not interfering with thymocytes maturation and no livertox-inducing properties. With new frontrunners (e.g., ABBV-157 (cedirogant), BI 730357 or IMU-935) this is still an exciting time for this treatment approach.
Collapse
|
10
|
Hall A, Chanteux H, Ménochet K, Ledecq M, Schulze MSED. Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches. J Med Chem 2021; 64:6413-6522. [PMID: 34003642 DOI: 10.1021/acs.jmedchem.0c02245] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
This perspective discusses the role of pregnane xenobiotic receptor (PXR) in drug discovery and the impact of its activation on CYP3A4 induction. The use of structural biology to reduce PXR activity on drug discovery projects has become more common in recent years. Analysis of this work highlights several important molecular interactions, and the resultant structural modifications to reduce PXR activity are summarized. The computational approaches undertaken to support the design of new drugs devoid of PXR activation potential are also discussed. Finally, the SAR of empirical design strategies to reduce PXR activity is reviewed, and the key SAR transformations are discussed and summarized. In conclusion, this perspective demonstrates that PXR activity can be greatly diminished or negated on active drug discovery projects with the knowledge now available. This perspective should be useful to anyone who seeks to reduce PXR activity on a drug discovery project.
Collapse
Affiliation(s)
- Adrian Hall
- UCB, Avenue de l'Industrie, Braine-L'Alleud 1420, Belgium
| | | | | | - Marie Ledecq
- UCB, Avenue de l'Industrie, Braine-L'Alleud 1420, Belgium
| | | |
Collapse
|
11
|
Karmakar A, Nimje RY, Silamkoti A, Pitchai M, Basha M, Singarayer C, Ramasamy D, Babu GTV, Samikannu R, Subramaniam S, Anjanappa P, Vetrichelvan M, Kumar H, Dikundwar AG, Gupta A, Gupta AK, Rampulla R, Dhar TGM, Mathur A. Practical Synthesis of (3aR, 9bR)-8-Fluoro-7-(perfluoropropan-2-yl)-9b-(phenylsulfonyl)-2,3,3a,4,5,9b-hexahydro-1H-benzo[e]indole: An Advanced Intermediate to Access the RORγt Inverse Agonist BMT-362265. Org Process Res Dev 2021. [DOI: 10.1021/acs.oprd.1c00019] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Ananta Karmakar
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra-Jigani Road, Bangalore 560099, India
| | - Roshan Y. Nimje
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra-Jigani Road, Bangalore 560099, India
| | - Arundutt Silamkoti
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra-Jigani Road, Bangalore 560099, India
| | - Manivel Pitchai
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra-Jigani Road, Bangalore 560099, India
| | - Mushkin Basha
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra-Jigani Road, Bangalore 560099, India
| | - Christuraj Singarayer
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra-Jigani Road, Bangalore 560099, India
| | - Duraisamy Ramasamy
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra-Jigani Road, Bangalore 560099, India
| | - G. T. Venkatesh Babu
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra-Jigani Road, Bangalore 560099, India
| | - Ramesh Samikannu
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra-Jigani Road, Bangalore 560099, India
| | - Srinath Subramaniam
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra-Jigani Road, Bangalore 560099, India
| | - Prakash Anjanappa
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra-Jigani Road, Bangalore 560099, India
| | - Muthalagu Vetrichelvan
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra-Jigani Road, Bangalore 560099, India
| | - Hemantha Kumar
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra-Jigani Road, Bangalore 560099, India
| | - Amol G. Dikundwar
- Analytical Research & Development, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra-Jigani Road, Bangalore 560099, India
| | - Anuradha Gupta
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra-Jigani Road, Bangalore 560099, India
| | - Arun Kumar Gupta
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra-Jigani Road, Bangalore 560099, India
| | - Richard Rampulla
- Small Molecule Drug Discovery, Bristol Myers Squibb Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-4000, United States
| | - T. G. Murali Dhar
- Small Molecule Drug Discovery, Bristol Myers Squibb Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-4000, United States
| | - Arvind Mathur
- Small Molecule Drug Discovery, Bristol Myers Squibb Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-4000, United States
| |
Collapse
|
12
|
Ruan Z, Park PK, Wei D, Purandare A, Wan H, O'Malley D, Stachura S, Perez H, Cavallaro CL, Weigelt CA, Sack JS, Ruzanov M, Khan J, Gururajan M, Wong JJ, Huang Y, Yarde M, Li Z, Chen C, Sun H, Borowski V, Xie JH, Anthony M, Agler M, Fink BE, Harikrishnan LS. Substituted diaryl ether compounds as retinoic acid-related orphan Receptor-γt (RORγt) agonists. Bioorg Med Chem Lett 2021; 35:127778. [PMID: 33422603 DOI: 10.1016/j.bmcl.2021.127778] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Revised: 12/18/2020] [Accepted: 12/31/2020] [Indexed: 11/26/2022]
Abstract
The discovery of a series of substituted diarylether compounds as retinoic acid related orphan receptor γt (RORγt) agonists is described. Compound 1 was identified from deck mining as a RORγt agonist. Hit-to-lead optimization led to the identification of lead compound 5, which possesses improved potency (10x). Extensive SAR exploration led to the identification of a potent and selective compound 22, that demonstrated an improved pharmacokinetic profile and a dose-dependent pharmacodynamic response. However, when dosed in a MC38 syngeneic tumor model, no evidence of efficacy was observed. ©2020 Elsevier Science Ltd. All rights reserved.
Collapse
Affiliation(s)
- Zheming Ruan
- Department of Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA.
| | - Peter K Park
- Department of Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Donna Wei
- Department of Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Ashok Purandare
- Department of Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Honghe Wan
- Department of Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Daniel O'Malley
- Department of Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Sylwia Stachura
- Department of Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Heidi Perez
- Department of Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Cullen L Cavallaro
- Department of Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Carolyn A Weigelt
- Molecular Structure & Design, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - John S Sack
- Molecular Structure & Design, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Max Ruzanov
- Molecular Structure & Design, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Javed Khan
- Molecular Structure & Design, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Murali Gururajan
- Immuno-Oncology Small Molecule Biology, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Jessica J Wong
- Immuno-Oncology Small Molecule Biology, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Yanling Huang
- Immuno-Oncology Small Molecule Biology, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Melissa Yarde
- Lead Discovery & Optimization, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Zhuyin Li
- Lead Discovery & Optimization, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Cliff Chen
- Preclinical Candidate Optimization, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Huadong Sun
- Preclinical Candidate Optimization, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Virna Borowski
- In vivo Pharmacology, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Jenny H Xie
- In vivo Pharmacology, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Monique Anthony
- Lead Discovery & Optimization, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Michele Agler
- Lead Discovery & Optimization, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Brian E Fink
- Department of Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| | - Lalgudi S Harikrishnan
- Department of Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA
| |
Collapse
|
13
|
Xia Y, Yu M, Zhao Y, Xia L, Huang Y, Sun N, Song M, Guo H, Zhang Y, Zhu D, Xie Q, Wang Y. Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORγt agonists. Eur J Med Chem 2020; 211:113013. [PMID: 33272782 DOI: 10.1016/j.ejmech.2020.113013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Revised: 10/24/2020] [Accepted: 11/09/2020] [Indexed: 01/01/2023]
Abstract
The retinoic acid receptor-related orphan receptor γt (RORγt) is an important nuclear receptor that regulates the differentiation of Th17 cells and production of interleukin 17(IL-17). RORγt agonists increase basal activity of RORγt and could provide a potential approach to cancer immunotherapy. Herein, hit compound 1 was identified as a weak RORγt agonist during in-house library screening. Changes in LHS core of 1 led to the identification of tetrahydroquinoline compound 6 as a partial RORγt agonist (max. act. = 39.3%). Detailed structure-activity relationship on substituent of the LHS core, amide linker and RHS arylsulfonyl moiety was explored and a novel series of tetrahydroquinolines and benzomorpholines was discovered as potent RORγt agonists. Tetrahydroquinoline compound 8g (EC50 = 8.9 ± 0.4 nM, max. act. = 104.5%) and benzomorpholine compound 9g (EC50 = 7.5 ± 0.6 nM, max. act. = 105.8%) were representative compounds with high RORγt agonistic activity in dual FRET assay, and they showed good activity in cell-based Gal4 reporter gene assay and Th17 cell differentiation assay (104.5% activation at 300 nM of 8g; 59.4% activation at 300 nM of 9g). The binding modes of 8g and 9g as well as the two RORγt inverse agonists accidentally discovered were also discussed.
Collapse
Affiliation(s)
- Yuehan Xia
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 ZhanghengRoad, Pudong, Shanghai, 201203, China
| | - Mingcheng Yu
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 ZhanghengRoad, Pudong, Shanghai, 201203, China
| | - Yunpeng Zhao
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 ZhanghengRoad, Pudong, Shanghai, 201203, China
| | - Li Xia
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 ZhanghengRoad, Pudong, Shanghai, 201203, China
| | - Yafei Huang
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 ZhanghengRoad, Pudong, Shanghai, 201203, China
| | - Nannan Sun
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 ZhanghengRoad, Pudong, Shanghai, 201203, China; Key Laboratory of Metabolism and Molecular Medicine, The Ministry of Education, Department of Biochemistry and Molecular Biology, Shanghai Medical College, Fudan University, Shanghai, 201203, China
| | - Meiqi Song
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 ZhanghengRoad, Pudong, Shanghai, 201203, China
| | - Huimin Guo
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 ZhanghengRoad, Pudong, Shanghai, 201203, China
| | - Yunyi Zhang
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 ZhanghengRoad, Pudong, Shanghai, 201203, China
| | - Di Zhu
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 ZhanghengRoad, Pudong, Shanghai, 201203, China
| | - Qiong Xie
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 ZhanghengRoad, Pudong, Shanghai, 201203, China; Fudan Zhangjiang Institute, Shanghai, 201203, China.
| | - Yonghui Wang
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 ZhanghengRoad, Pudong, Shanghai, 201203, China.
| |
Collapse
|
14
|
Takahashi K, Ano Y, Chatani N. Fluoride anion-initiated bis-trifluoromethylation of phenyl aromatic carboxylates with (trifluoromethyl)trimethylsilane. Chem Commun (Camb) 2020; 56:11661-11664. [PMID: 33000827 DOI: 10.1039/d0cc04826g] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The fluoride anion-initiated reaction of phenyl aromatic carboxylates with (trifluoromethyl)trimethylsilane (Me3SiCF3) that results in the formation of O-silyl-protected 2-aryl-1,1,1,3,3,3-hexafluoroisopropanols is reported. A phenoxide anion, generated during the trifluoromethylation of the phenyl carboxylate, also activates the Me3SiCF3, which permits a catalytic amount of the fluoride anion source to be used. Various functional groups, which can be used for further elaboration, are tolerated in the reaction.
Collapse
Affiliation(s)
- Kenjiro Takahashi
- Department of Applied Chemistry, Faculty of Engineering, Osaka University, Suita, Osaka 565-0871, Japan.
| | - Yusuke Ano
- Department of Applied Chemistry, Faculty of Engineering, Osaka University, Suita, Osaka 565-0871, Japan. and Center for Atomic and Molecular Technologies, Graduate School of Engineering, Osaka University, Suita, Osaka 565-0871, Japan
| | - Naoto Chatani
- Department of Applied Chemistry, Faculty of Engineering, Osaka University, Suita, Osaka 565-0871, Japan.
| |
Collapse
|
15
|
Marcoux D, Bertrand MB, Weigelt CA, Yip S, Galella M, Park H, Wu DR, Wang J, Yarde M, Cvijic ME, Li S, Hynes J, Tino JA, Zhao Q, Dhar TM. Annulation reaction enables the identification of an exocyclic amide tricyclic chemotype as retinoic acid Receptor-Related orphan receptor gamma (RORγ/RORc) inverse agonists. Bioorg Med Chem Lett 2020; 30:127466. [DOI: 10.1016/j.bmcl.2020.127466] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Revised: 07/28/2020] [Accepted: 08/02/2020] [Indexed: 02/07/2023]
|
16
|
Jiang B, Duan JJW, Stachura S, Karmakar A, Hemagiri H, Raut DK, Gupta AK, Weigelt CA, Khan J, Sack JS, Wu DR, Yarde M, Shen DR, Galella MA, Mathur A, Zhao Q, Salter-Cid LM, Carter PH, Dhar TGM. Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidines as novel RORγt inverse agonists. Bioorg Med Chem Lett 2020; 30:127392. [PMID: 32738966 DOI: 10.1016/j.bmcl.2020.127392] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Revised: 06/29/2020] [Accepted: 07/03/2020] [Indexed: 02/06/2023]
Abstract
A novel series of cis-3,4-diphenylpyrrolidines were designed as RORγt inverse agonists based on the binding conformation of previously reported bicyclic sulfonamide 1. Preliminary synthesis and structure-activity relationship (SAR) study established (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidine as the most effective scaffold. Subsequent SAR optimization led to identification of a piperidinyl carboxamide 31, which was potent against RORγt (EC50 of 61 nM in an inverse agonist assay), selective relative to RORα, RORβ, LXRα and LXRβ, and stable in human and mouse liver microsomes. Furthermore, compound 31 exhibited considerably lower PXR Ymax (46%) and emerged as a promising lead. The binding mode of the diphenylpyrrolidine series was established with an X-ray co-crystal structure of 10A/RORγt.
Collapse
Affiliation(s)
- Bin Jiang
- Research and Early Development, Bristol Myers Squibb Company, Princeton, NJ 08543-4000, United States.
| | - James J-W Duan
- Research and Early Development, Bristol Myers Squibb Company, Princeton, NJ 08543-4000, United States.
| | - Sylwia Stachura
- Research and Early Development, Bristol Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Ananta Karmakar
- Bristol Myers Squibb-Biocon Research Center, Bangalore, India
| | | | | | | | - Carolyn A Weigelt
- Research and Early Development, Bristol Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Javed Khan
- Research and Early Development, Bristol Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - John S Sack
- Research and Early Development, Bristol Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Dauh-Rurng Wu
- Research and Early Development, Bristol Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Melissa Yarde
- Research and Early Development, Bristol Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Ding-Ren Shen
- Research and Early Development, Bristol Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Michael A Galella
- Research and Early Development, Bristol Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Arvind Mathur
- Research and Early Development, Bristol Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Qihong Zhao
- Research and Early Development, Bristol Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Luisa M Salter-Cid
- Research and Early Development, Bristol Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Percy H Carter
- Research and Early Development, Bristol Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - T G Murali Dhar
- Research and Early Development, Bristol Myers Squibb Company, Princeton, NJ 08543-4000, United States
| |
Collapse
|
17
|
Boardman DA, Garcia RV, Ivison SM, Bressler B, Dhar TGM, Zhao Q, Levings MK. Pharmacological inhibition of RORC2 enhances human Th17‐Treg stability and function. Eur J Immunol 2020; 50:1400-1411. [DOI: 10.1002/eji.201948435] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2019] [Revised: 03/19/2020] [Accepted: 05/04/2020] [Indexed: 12/11/2022]
Affiliation(s)
- Dominic A. Boardman
- Department of SurgeryThe University of British ColumbiaColumbia Vancouver British Columbia Canada
- BC Children's Hospital Research Institute Vancouver British Columbia Canada
| | - Rosa V. Garcia
- Department of SurgeryThe University of British ColumbiaColumbia Vancouver British Columbia Canada
- BC Children's Hospital Research Institute Vancouver British Columbia Canada
| | - Sabine M. Ivison
- Department of SurgeryThe University of British ColumbiaColumbia Vancouver British Columbia Canada
- BC Children's Hospital Research Institute Vancouver British Columbia Canada
| | - Brian Bressler
- Department of MedicineThe University of British Columbia Vancouver British Columbia Canada
| | - TG Murali Dhar
- Research and DevelopmentBristol–Myers Squibb Princeton NJ USA
| | - Qihong Zhao
- Research and DevelopmentBristol–Myers Squibb Princeton NJ USA
| | - Megan K. Levings
- Department of SurgeryThe University of British ColumbiaColumbia Vancouver British Columbia Canada
- BC Children's Hospital Research Institute Vancouver British Columbia Canada
| |
Collapse
|
18
|
Bower MJ, Aronov AM, Cleveland T, Hariparsad N, McGaughey GB, McMasters DR, Zhang X, Goldman B. Smallest Maximum Intramolecular Distance: A Novel Method to Mitigate Pregnane Xenobiotic Receptor Activation. J Chem Inf Model 2020; 60:2091-2099. [DOI: 10.1021/acs.jcim.9b00692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Michael J. Bower
- Vertex Pharmaceuticals, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Alex M. Aronov
- Vertex Pharmaceuticals, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Thomas Cleveland
- Vertex Pharmaceuticals, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Niresh Hariparsad
- Vertex Pharmaceuticals, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Georgia B. McGaughey
- Vertex Pharmaceuticals, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Daniel R. McMasters
- Vertex Pharmaceuticals, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Xiaodan Zhang
- Vertex Pharmaceuticals, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Brian Goldman
- Vertex Pharmaceuticals, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| |
Collapse
|
19
|
Sato A, Fukase Y, Kono M, Ochida A, Oda T, Sasaki Y, Ishii N, Tomata Y, Fukumoto S, Imai YN, Uga K, Shibata A, Yamasaki M, Nakagawa H, Shirasaki M, Skene R, Hoffman I, Sang B, Snell G, Shirai J, Yamamoto S. Design and Synthesis of Conformationally Constrained RORγt Inverse Agonists. ChemMedChem 2019; 14:1917-1932. [DOI: 10.1002/cmdc.201900416] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 10/04/2019] [Indexed: 11/10/2022]
Affiliation(s)
- Ayumu Sato
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
- Axcelead Drug Discovery Partners, Inc. 26-1, Muraoka-Higashi 2-Chome, Fujisawa Kanagawa 251-0012 Japan
| | - Yoshiyuki Fukase
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
- Tri-Institutional Therapeutics Discovery Institute, Inc. 413 East 69th Street New York NY 10021 USA
| | - Mitsunori Kono
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Atsuko Ochida
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Tsuneo Oda
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Yusuke Sasaki
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Naoki Ishii
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Yoshihide Tomata
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Shoji Fukumoto
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
- Japan Tobacco Inc.Central Pharmaceutical Research Institute 1-1 Murasaki-cho Takatsuki, Osaka 569-1125 Japan
| | - Yumi N. Imai
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
- Chordia Therapeutics Inc. 26-1, Muraoka-Higashi 2-Chome, Fujisawa Kanagawa 251-0012 Japan
| | - Keiko Uga
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
- Axcelead Drug Discovery Partners, Inc. 26-1, Muraoka-Higashi 2-Chome, Fujisawa Kanagawa 251-0012 Japan
| | - Akira Shibata
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Masashi Yamasaki
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
- Axcelead Drug Discovery Partners, Inc. 26-1, Muraoka-Higashi 2-Chome, Fujisawa Kanagawa 251-0012 Japan
| | - Hideyuki Nakagawa
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Mikio Shirasaki
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
- Axcelead Drug Discovery Partners, Inc. 26-1, Muraoka-Higashi 2-Chome, Fujisawa Kanagawa 251-0012 Japan
| | - Robert Skene
- Takeda California, Inc.10410 Science Center Drive San Diego CA 92121 USA
| | - Isaac Hoffman
- Takeda California, Inc.10410 Science Center Drive San Diego CA 92121 USA
| | - Bi‐Ching Sang
- Takeda California, Inc.10410 Science Center Drive San Diego CA 92121 USA
| | - Gyorgy Snell
- Takeda California, Inc.10410 Science Center Drive San Diego CA 92121 USA
| | - Junya Shirai
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
- Cardurion Pharmaceuticals K.K. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Satoshi Yamamoto
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| |
Collapse
|
20
|
Marcoux D, Duan JJW, Shi Q, Cherney RJ, Srivastava AS, Cornelius L, Batt DG, Liu Q, Beaudoin-Bertrand M, Weigelt CA, Khandelwal P, Vishwakrishnan S, Selvakumar K, Karmakar A, Gupta AK, Basha M, Ramlingam S, Manjunath N, Vanteru S, Karmakar S, Maddala N, Vetrichelvan M, Gupta A, Rampulla RA, Mathur A, Yip S, Li P, Wu DR, Khan J, Ruzanov M, Sack JS, Wang J, Yarde M, Cvijic ME, Li S, Shuster DJ, Borowski V, Xie JH, McIntyre KW, Obermeier MT, Fura A, Stefanski K, Cornelius G, Hynes J, Tino JA, Macor JE, Salter-Cid L, Denton R, Zhao Q, Carter PH, Dhar TGM. Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy. J Med Chem 2019; 62:9931-9946. [PMID: 31638797 DOI: 10.1021/acs.jmedchem.9b01369] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
RORγt is an important nuclear receptor that regulates the production of several pro-inflammatory cytokines such as IL-17 and IL-22. As a result, RORγt has been identified as a potential target for the treatment of various immunological disorders such as psoriasis, psoriatic arthritis, and inflammatory bowel diseases. Structure and computer-assisted drug design led to the identification of a novel series of tricyclic RORγt inverse agonists with significantly improved in vitro activity in the reporter (Gal4) and human whole blood assays compared to our previous chemotype. Through careful structure activity relationship, several potent and selective RORγt inverse agonists have been identified. Pharmacokinetic studies allowed the identification of the lead molecule 32 with a low peak-to-trough ratio. This molecule showed excellent activity in an IL-2/IL-23-induced mouse pharmacodynamic study and demonstrated biologic-like efficacy in an IL-23-induced preclinical model of psoriasis.
Collapse
Affiliation(s)
- David Marcoux
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - James J-W Duan
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Qing Shi
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Robert J Cherney
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Anurag S Srivastava
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Lyndon Cornelius
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Douglas G Batt
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Qingjie Liu
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Myra Beaudoin-Bertrand
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Carolyn A Weigelt
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Purnima Khandelwal
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Sureshbabu Vishwakrishnan
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Kumaravel Selvakumar
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Ananta Karmakar
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Arun Kumar Gupta
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Mushkin Basha
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Sridharan Ramlingam
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Naveen Manjunath
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Sridhar Vanteru
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Sukhen Karmakar
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Nageswara Maddala
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Muthalagu Vetrichelvan
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Anuradha Gupta
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Richard A Rampulla
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Arvind Mathur
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Shiuhang Yip
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Peng Li
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Dauh-Rurng Wu
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Javed Khan
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Max Ruzanov
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - John S Sack
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Jinhong Wang
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Melissa Yarde
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Mary Ellen Cvijic
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Sha Li
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - David J Shuster
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Virna Borowski
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Jenny H Xie
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Kim W McIntyre
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Mary T Obermeier
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Aberra Fura
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Kevin Stefanski
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Georgia Cornelius
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - John Hynes
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Joseph A Tino
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - John E Macor
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Luisa Salter-Cid
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Rex Denton
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Qihong Zhao
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Percy H Carter
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - T G Murali Dhar
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| |
Collapse
|
21
|
Sun N, Guo H, Wang Y. Retinoic acid receptor-related orphan receptor gamma-t (RORγt) inhibitors in clinical development for the treatment of autoimmune diseases: a patent review (2016-present). Expert Opin Ther Pat 2019; 29:663-674. [DOI: 10.1080/13543776.2019.1655541] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Nannan Sun
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, China
| | - Huimin Guo
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, China
| | - Yonghui Wang
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, China
| |
Collapse
|
22
|
Lu Z, Duan JJW, Xiao H, Neels J, Wu DR, Weigelt CA, Sack JS, Khan J, Ruzanov M, An Y, Yarde M, Karmakar A, Vishwakrishnan S, Baratam V, Shankarappa H, Vanteru S, Babu V, Basha M, Kumar Gupta A, Kumaravel S, Mathur A, Zhao Q, Salter-Cid LM, Carter PH, Murali Dhar T. Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists. Bioorg Med Chem Lett 2019; 29:2265-2269. [DOI: 10.1016/j.bmcl.2019.06.036] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Revised: 06/11/2019] [Accepted: 06/19/2019] [Indexed: 11/25/2022]
|
23
|
Amaudrut J, Argiriadi MA, Barth M, Breinlinger EC, Bressac D, Broqua P, Calderwood DJ, Chatar M, Cusack KP, Gauld SB, Jacquet S, Kamath RV, Kort ME, Lepais V, Luccarini JM, Masson P, Montalbetti C, Mounier L, Potin D, Poupardin O, Rouaud S, Spitzer L, Wallace CD. Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists. Bioorg Med Chem Lett 2019; 29:1799-1806. [DOI: 10.1016/j.bmcl.2019.05.015] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Revised: 05/02/2019] [Accepted: 05/07/2019] [Indexed: 01/08/2023]
|
24
|
Duan JJW, Lu Z, Jiang B, Stachura S, Weigelt CA, Sack JS, Khan J, Ruzanov M, Galella MA, Wu DR, Yarde M, Shen DR, Shuster DJ, Borowski V, Xie JH, Zhang L, Vanteru S, Gupta AK, Mathur A, Zhao Q, Foster W, Salter-Cid LM, Carter PH, Dhar TGM. Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse Agonists. ACS Med Chem Lett 2019; 10:367-373. [PMID: 30891142 DOI: 10.1021/acsmedchemlett.9b00010] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2019] [Accepted: 02/25/2019] [Indexed: 01/12/2023] Open
Abstract
A new phenyl (3-phenylpyrrolidin-3-yl)sulfone series of RORγt inverse agonists was discovered utilizing the binding conformation of previously reported bicyclic sulfonamide 1. Through a combination of structure-based design and structure-activity relationship studies, a polar set of amides at N1-position of the pyrrolidine ring and perfluoroisopropyl group at para-position of the 3-phenyl group were identified as critical structural elements to achieve high selectivity against PXR, LXRα, and LXRβ. Further optimization led to the discovery of (1R,4r)-4-((R)-3-((4-fluorophenyl)sulfonyl)-3-(4-(perfluoropropan-2-yl)phenyl)pyrrolidine-1-carbonyl)cyclohexane-1-carboxylic acid (26), which displayed excellent selectivity, desirable liability and pharmacokinetic properties in vitro, and a good pharmacokinetic profile in mouse. Oral administration of 26 demonstrated dose-dependent inhibition of IL-17 production in a mouse IL-2/IL-23-induced pharmacodynamic model and biologic-like efficacy in an IL-23-induced mouse acanthosis model.
Collapse
Affiliation(s)
- James J.-W. Duan
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Zhonghui Lu
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Bin Jiang
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Sylwia Stachura
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Carolyn A. Weigelt
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - John S. Sack
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Javed Khan
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Max Ruzanov
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Michael A. Galella
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Dauh-Rurng Wu
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Melissa Yarde
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Ding-Ren Shen
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - David J. Shuster
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Virna Borowski
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Jenny H. Xie
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Lisa Zhang
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Sridhar Vanteru
- Bristol-Myers Squibb-Biocon Research Center, Bangalore 560099, India
| | - Arun Kumar Gupta
- Bristol-Myers Squibb-Biocon Research Center, Bangalore 560099, India
| | - Arvind Mathur
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Qihong Zhao
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - William Foster
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Luisa M. Salter-Cid
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Percy H. Carter
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - T. G. Murali Dhar
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| |
Collapse
|
25
|
Kotoku M, Maeba T, Fujioka S, Yokota M, Seki N, Ito K, Suwa Y, Ikenogami T, Hirata K, Hase Y, Katsuda Y, Miyagawa N, Arita K, Asahina K, Noguchi M, Nomura A, Doi S, Adachi T, Crowe P, Tao H, Thacher S, Hashimoto H, Suzuki T, Shiozaki M. Discovery of Second Generation RORγ Inhibitors Composed of an Azole Scaffold. J Med Chem 2019; 62:2837-2842. [PMID: 30776227 DOI: 10.1021/acs.jmedchem.8b01567] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Starting from a previously reported RORγ inhibitor (1), successive efforts to improve in vivo potency were continued. Introduction of metabolically beneficial motifs in conjunction with scaffold hopping was examined, resulting in discovery of the second generation RORγ inhibitor composed of a 4-(isoxazol-3-yl)butanoic acid scaffold (24). Compound 24 achieved a 10-fold improvement in in vivo potency in a mouse CD3 challenge model along with significant anti-inflammatory effects in a mouse dermatitis model.
Collapse
Affiliation(s)
- Masayuki Kotoku
- Graduate School of Medical Science , Kyoto Prefectural University of Medicine , 1-5 Shimogamo-hangi-cho , Sakyo-ku , Kyoto 603-0823 , Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Paul Crowe
- Orphagen Pharmaceuticals , 11558 Sorrento Valley Road, Suite 4 , San Diego , California 92121 , United States
| | - Haiyan Tao
- Orphagen Pharmaceuticals , 11558 Sorrento Valley Road, Suite 4 , San Diego , California 92121 , United States
| | - Scott Thacher
- Orphagen Pharmaceuticals , 11558 Sorrento Valley Road, Suite 4 , San Diego , California 92121 , United States
| | | | - Takayoshi Suzuki
- Graduate School of Medical Science , Kyoto Prefectural University of Medicine , 1-5 Shimogamo-hangi-cho , Sakyo-ku , Kyoto 603-0823 , Japan
| | | |
Collapse
|
26
|
Sun M, He C, Chen L, Yang W, Wu W, Chen F, Cao AT, Yao S, Dann SM, Dhar TGM, Salter-Cid L, Zhao Q, Liu Z, Cong Y. RORγt Represses IL-10 Production in Th17 Cells To Maintain Their Pathogenicity in Inducing Intestinal Inflammation. THE JOURNAL OF IMMUNOLOGY 2018; 202:79-92. [PMID: 30478092 DOI: 10.4049/jimmunol.1701697] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2017] [Accepted: 10/25/2018] [Indexed: 01/20/2023]
Abstract
The role of retinoid-related orphan receptor γ t (RORγt) in Th17 cell differentiation has been well established; however, how it regulates other T cell lineages is still not clearly understood. In this study, we report that in mice, while promoting Th17 cell differentiation, RORγt inhibited IL-10 production by T cells, thereby preserving the pathogenicity of Th17 cells. Treatment with RORγt-specific inhibitor suppressed Th17 cell signature cytokines, but promoted IL-10 production. RORγt inhibitor-treated Th17 cells induce less severe colitis compared with control Th17 cells. Mechanistically, the RORγt inhibitor induced T cell expression of Blimp-1 (encoded by Prdm1). Prdm1-/- T cells produced significantly fewer IL-10 when treated with RORγt inhibitor compared with wild-type T cells. Furthermore, RORγt inhibitor-treated Prdm1-/- Th17 cells induce more severe colitis compared with RORγt inhibitor-treated wild-type Th17 cells. Collectively, our studies reveal a novel mechanism by which RORγt drives and maintains pathogenic Th17 cell development by inhibiting IL-10 production.
Collapse
Affiliation(s)
- Mingming Sun
- Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX 77555.,Department of Gastroenterology, The Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China
| | - Chong He
- Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX 77555.,Department of Gastroenterology, The Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China
| | - Liang Chen
- Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX 77555.,Department of Gastroenterology, The Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China
| | - Wenjing Yang
- Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX 77555.,Department of Gastroenterology, The Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China
| | - Wei Wu
- Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX 77555.,Department of Gastroenterology, The Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China
| | - Feidi Chen
- Department of Pathology, The University of Texas Medical Branch, Galveston, TX 77555
| | - Anthony T Cao
- Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX 77555
| | - Suxia Yao
- Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX 77555
| | - Sara M Dann
- Department of Internal Medicine, The University of Texas Medical Branch, Galveston, TX 77555; and
| | | | | | | | - Zhanju Liu
- Department of Gastroenterology, The Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China;
| | - Yingzi Cong
- Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX 77555; .,Department of Pathology, The University of Texas Medical Branch, Galveston, TX 77555
| |
Collapse
|
27
|
Noguchi M, Nomura A, Doi S, Yamaguchi K, Hirata K, Shiozaki M, Maeda K, Hirashima S, Kotoku M, Yamaguchi T, Katsuda Y, Crowe P, Tao H, Thacher S, Adachi T. Ternary crystal structure of human RORγ ligand-binding-domain, an inhibitor and corepressor peptide provides a new insight into corepressor interaction. Sci Rep 2018; 8:17374. [PMID: 30478402 PMCID: PMC6255837 DOI: 10.1038/s41598-018-35783-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2018] [Accepted: 11/12/2018] [Indexed: 01/08/2023] Open
Abstract
Retinoic acid-related orphan receptor gamma (RORγ) plays pivotal roles in autoimmune diseases by controlling the lineage of interleukin 17 (IL-17)-producing CD4+ T cells (Th17 cells). Structure-based drug design has proven fruitful in the development of inhibitors targeting the ligand binding domain (LBD) of RORγ. Here, we present the crystal structure of a novel RORγ inhibitor co-complex, in the presence of a corepressor (CoR) peptide. This ternary complex with compound T reveals the structural basis for an inhibitory mechanism different from the previously reported inverse agonist. Compared to the inverse agonist, compound T induces about 2 Å shift of helix 5 (H5) backbone and side-chain conformational changes of Met365 on H5. These conformational changes correlate to reduced CoR peptide binding to RORγ-LBD in the presence of compound T, which suggests that the shift of H5 is responsible. This crystal structure analysis will provide useful information for the development of novel and efficacious drugs for autoimmune disorders.
Collapse
Affiliation(s)
- Masato Noguchi
- Pharmaceutical Frontier Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-13-2, Fukuura, Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan.
| | - Akihiro Nomura
- Pharmaceutical Frontier Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-13-2, Fukuura, Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan
| | - Satoki Doi
- Pharmaceutical Frontier Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-13-2, Fukuura, Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan
| | - Keishi Yamaguchi
- Pharmaceutical Frontier Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-13-2, Fukuura, Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan
| | - Kazuyuki Hirata
- Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka, 569-1125, Japan
| | - Makoto Shiozaki
- Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka, 569-1125, Japan
| | - Katsuya Maeda
- Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka, 569-1125, Japan
| | - Shintaro Hirashima
- Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka, 569-1125, Japan
| | - Masayuki Kotoku
- Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka, 569-1125, Japan
| | - Takayuki Yamaguchi
- Biological Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka, 569-1125, Japan
| | - Yoshiaki Katsuda
- Biological Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka, 569-1125, Japan
| | - Paul Crowe
- Orphagen Pharmaceuticals, 11558 Sorrento Valley Road, Suite 4, San Diego, California, 92121, USA
| | - Haiyan Tao
- Orphagen Pharmaceuticals, 11558 Sorrento Valley Road, Suite 4, San Diego, California, 92121, USA
| | - Scott Thacher
- Orphagen Pharmaceuticals, 11558 Sorrento Valley Road, Suite 4, San Diego, California, 92121, USA
| | - Tsuyoshi Adachi
- Pharmaceutical Frontier Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-13-2, Fukuura, Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan.
| |
Collapse
|
28
|
Narjes F, Xue Y, von Berg S, Malmberg J, Llinas A, Olsson RI, Jirholt J, Grindebacke H, Leffler A, Hossain N, Lepistö M, Thunberg L, Leek H, Aagaard A, McPheat J, Hansson EL, Bäck E, Tångefjord S, Chen R, Xiong Y, Hongbin G, Hansson TG. Potent and Orally Bioavailable Inverse Agonists of RORγt Resulting from Structure-Based Design. J Med Chem 2018; 61:7796-7813. [DOI: 10.1021/acs.jmedchem.8b00783] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Linda Thunberg
- Early Product Development, Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, SE-43183 Mölndal, Sweden
| | - Hanna Leek
- Early Product Development, Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, SE-43183 Mölndal, Sweden
| | | | | | | | | | | | - Rongfeng Chen
- Pharmaron Beijing Company, Ltd., Taihe Road, BDA, Beijing 100176, PR China
| | - Yao Xiong
- Pharmaron Beijing Company, Ltd., Taihe Road, BDA, Beijing 100176, PR China
| | - Ge Hongbin
- Pharmaron Beijing Company, Ltd., Taihe Road, BDA, Beijing 100176, PR China
| | | |
Collapse
|
29
|
Pandya VB, Kumar S, Sachchidanand, Sharma R, Desai RC. Combating Autoimmune Diseases With Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc) Inhibitors: Hits and Misses. J Med Chem 2018; 61:10976-10995. [DOI: 10.1021/acs.jmedchem.8b00588] [Citation(s) in RCA: 74] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Vrajesh B. Pandya
- Zydus Research Centre, Cadila Healthcare Limited, Sarkhej Bavla NH8A, Moraiya, Ahmedabad 382210, India
| | - Sanjay Kumar
- Zydus Research Centre, Cadila Healthcare Limited, Sarkhej Bavla NH8A, Moraiya, Ahmedabad 382210, India
| | - Sachchidanand
- Zydus Research Centre, Cadila Healthcare Limited, Sarkhej Bavla NH8A, Moraiya, Ahmedabad 382210, India
| | - Rajiv Sharma
- Zydus Research Centre, Cadila Healthcare Limited, Sarkhej Bavla NH8A, Moraiya, Ahmedabad 382210, India
| | - Ranjit C. Desai
- Zydus Research Centre, Cadila Healthcare Limited, Sarkhej Bavla NH8A, Moraiya, Ahmedabad 382210, India
| |
Collapse
|
30
|
Buchman CD, Chai SC, Chen T. A current structural perspective on PXR and CAR in drug metabolism. Expert Opin Drug Metab Toxicol 2018; 14:635-647. [PMID: 29757018 DOI: 10.1080/17425255.2018.1476488] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
INTRODUCTION Pregnane X receptor (PXR) and the constitutive androstane receptor (CAR) are two members of the nuclear receptor superfamily that play major roles in the expression of various drug metabolism enzymes and are known for their ligand promiscuity. As with other nuclear receptors, PXR and CAR are each composed of a ligand-binding domain (LBD) and a DNA-binding domain (DBD) connected by a hinge region. Areas covered: This review focuses on the information obtained over the last 15+ years from X-ray crystallography studies of the structure of PXR and CAR. Areas of focus include the mobility of each structure, based on temperature factors (B factors); multimeric interactions; the binding of coregulators and ligands; and how the crystal structures were obtained. The first use of hydrogen-deuterium exchange coupled with mass spectroscopy (HDX-MS) to study compound-protein interactions in the PXR-LBD is also addressed. Expert opinion: X-ray crystallography studies have provided us with an excellent understanding of how the LBDs of each receptor function; however, many questions remain concerning the structure of these receptors. Future research should focus on determining the co-crystal structure of an antagonist bound to PXR and on studying the structural aspects of the full-length CAR and PXR proteins.
Collapse
Affiliation(s)
- Cameron D Buchman
- a Department of Chemical Biology and Therapeutics , St. Jude Children's Research Hospital , Memphis , TN , USA
| | - Sergio C Chai
- a Department of Chemical Biology and Therapeutics , St. Jude Children's Research Hospital , Memphis , TN , USA
| | - Taosheng Chen
- a Department of Chemical Biology and Therapeutics , St. Jude Children's Research Hospital , Memphis , TN , USA
| |
Collapse
|